SCHEMBL23927035

SCHEMBL23927035

COC(=O)Nc1cncnc1Cl

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.40
CHUK O15111 1/20 0.39
CSNK2A1 P68400 1/20 0.37
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
EGFR P00533 2/20 0.36
KDR P35968 2/20 0.36
PKM P14618 2/20 0.36
MAPT P10636 1/20 0.36
IRAK4 Q9NWZ3 1/20 0.35
HTT P42858 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.34
ALOX15 P16050 1/20 0.34
KDM4E B2RXH2 2/20 0.33
ALDH1A1 P00352 2/20 0.33
TYK2 P29597 2/20 0.33
MALT1 Q9UDY8 1/20 0.33
JAK2 O60674 1/20 0.33
JAK1 P23458 1/20 0.33
NPC1 O15118 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30079569 1.00 HPGD (0.40) HPGDCHUKCSNK2A1MEN1KMT2A
SCHEMBL30079663 0.84 ATR (0.46)
SCHEMBL23927012 0.84 ATR (0.46)
SCHEMBL23926998 0.84 ALDH1A1 (0.49) HPGDKMT2AEGFRKDRSMN1; SMN2
SCHEMBL30258095 0.84 ALDH1A1 (0.49) HPGDKMT2AEGFRKDRSMN1; SMN2
SCHEMBL16452808 0.82 PTK2 (0.43) HPGDCHUKMEN1KMT2AMAPT
SCHEMBL25256071 0.75 GPR35 (0.58) HPGDKMT2APKMMAPTSMN1; SMN2
SCHEMBL30770361 0.75 GPR35 (0.58) HPGDKMT2APKMMAPTSMN1; SMN2
SCHEMBL29030296 0.75 GPR35 (0.33) MEN1KMT2AHTTSMN1; SMN2ALDH1A1
SCHEMBL15223287 0.73 HPGD (0.41) HPGDCHUKMEN1KMT2AEGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230124087-A1 KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS HOFFMANN-LA ROCHE INC. (US) 2023-04-20 US disclosed
US-20230124087-A1 KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS HOFFMANN-LA ROCHE INC. (US) 2023-04-20 US disclosed
EP-4139306-A1 KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS F. Hoffmann-La Roche AG (CH) 2023-03-01 EP disclosed
CN-115380032-A KV3 enhancers for the treatment of cognitive disorders 豪夫迈·罗氏有限公司 2022-11-22 CN disclosed
WO-2021214090-A1 KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2021-10-28 WO disclosed
WO-2021214090-A1 KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2021-10-28 WO disclosed
EP-3901152-A1 KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS F. Hoffmann-La Roche AG (CH) 2021-10-27 EP disclosed
EP-3901152-A1 KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS F. Hoffmann-La Roche AG (CH) 2021-10-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230124087-A1 KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS KCNN3, KCNA4, KCNA3 HPGD 4541/4885CHUK 3341/4885CSNK2A1 1885/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.